

Technology Advisory Committee A Interests Register

Topic: Alpelisib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2 negative, PIK3CA-mutated breast cancer [ID3929]

Publication Date: 10/08/2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Holly Heath	Patient expert	Indirect - financial	In the last 12 months Breast Cancer Now has received funding from the manufacturer Novartis and possible comparator companies Lilly UK and Pfizer either towards our living with secondary breast cancer support service or our service pledge work with hospitals.	N/A	01.06.2021	N/A	It was agreed that her declaration would not prevent Holly from providing expert advice to the committee.
Dr Catherine Harper-Wynne	Clinical expert	Direct - financial	Dr Harper-Wynne has acted as an advisor on advisory boards for Novartis for other agents and received honoraria as chair of an educational meeting conducted by Novartis for this agent.	N/A	09.06.2021	N/A	It was agreed her declarations would not prevent Dr Harper-Wynne from providing expert advice to the committee.
Dr Alistair Ring	Clinical expert	Direct - financial	Dr Ring declared financial interests as he has received fees for consultancy from	N/A	07.06.2021	N/A	It was agreed his declarations would not prevent Dr Ring from

			Novartis and within the last 12 months and ongoing, he has conducted consultancy for companies with agents used to treat advanced and early breast cancer: Roche, Lilly, Pfizer, AstraZeneca, Daiichi Sankyo, MSD, and Gilead.				providing expert advice to the committee.
--	--	--	--	--	--	--	---